98%
921
2 minutes
20
Echinocandins, which target the fungal β-1,3-glucan synthase (Fks), are essential for treating invasive fungal infections, yet resistance is increasingly reported. While resistance typically arises through mutations in Fks hotspots, emerging evidence suggests a contributing role of changes in membrane sterol composition due to mutations. Here, we present a clinical case of () in which combined mutations in and , but not alone, appear to confer echinocandin resistance. Integrated analyses reveal a recurrent association between Erg3 loss-of-function and echinocandin resistance mediated by Fks variation across species, but exclude Erg3 loss-of-function as an independent resistance mechanism. Advances in Fks structural biology and insights into echinocandin-Fks interactions support a model of epistatic cross-talk between membrane sterols and Fks function. Understanding this interaction is crucial, as it may underlie not only acquired echinocandin resistance but also the broader development of multidrug resistance across major antifungal drug classes.IMPORTANCEA clinical case in which the combination of variation in a β‑1,3‑glucan synthase-encoding gene () and the sterol desaturase-encoding gene seems to underlie echinocandin resistance, prompted us to hypothesize that membrane sterol changes may modulate, rather than independently cause, Fks‑linked resistance. We were able to explore this hypothesis due to recent developments in the field, such as the release of the FungAMR database, which enables global co‑occurrence analyses; AI‑driven variant effect predictors such as Evolutionary Scale Modeling (ESM) that can explore the impact of thousands of alleles; the cryo‑EM resolution of the Fks1 protein; and the first mechanistic model of echinocandin‑Fks1 binding. Together, these advances provide the structural and computational framework needed to delineate our hypothesis that specific sterol variants might influence β‑1,3‑glucan synthase function and drug binding. Further surveillance of this potentially epistatic interaction can be of significant clinical importance amid rising multidrug‑resistant infections, as overlooking such interactions could lead to under‑calling resistance and misguided therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1128/mbio.01419-25 | DOI Listing |
mBio
September 2025
Department of Biology, Laboratory of Molecular Cell Biology, KU Leuven, Leuven, Flanders, Belgium.
Echinocandins, which target the fungal β-1,3-glucan synthase (Fks), are essential for treating invasive fungal infections, yet resistance is increasingly reported. While resistance typically arises through mutations in Fks hotspots, emerging evidence suggests a contributing role of changes in membrane sterol composition due to mutations. Here, we present a clinical case of () in which combined mutations in and , but not alone, appear to confer echinocandin resistance.
View Article and Find Full Text PDFCarbohydr Res
September 2025
Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India. Electronic address:
The growing prevalence of treatment-resistant Candida species highlights an urgent need for innovative antifungal therapies. The current range of antifungals, limited to polyenes, azoles, and echinocandins, are becoming insufficient due to the rise of resistance, including cross-resistance among fungal strains. Marine environment is an underexplored reservoir of unique enzymes which can be extremophilic.
View Article and Find Full Text PDFEur J Med Chem
August 2025
Chemobiology and Pharmacognosy for Health (CPS) Team, Strasbourg Institute for Drug Discovery and Development (ITI IMS), Laboratory of Therapeutic Innovation (LIT), UMR 7200 CNRS/Unistra, Faculty of Pharmacy, 74, route du Rhin, Illkirch, 67400, France; University of Strasbourg Institute for Advanced
Before the 2000s, the antifungal toolbox against invasive fungal infections (IFIs) was only composed of very toxic amphotericin B, weakly selective and nearly unused 5-fluorocytosine and azoles that have been massively used in agriculture and horticulture. The emergence of resistances followed their respective launch, so many antifungals became progressively inefficient whereas the antifungal research was left behind. In the 2000s, echinocandins (ECs) were introduced as a new antifungal class of natural origin and of unprecedented mechanism of action.
View Article and Find Full Text PDFCurr Pharm Des
August 2025
Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida-Uttar Pradesh, 201306, India.
The main culprit behind cutaneous candidiasis, a fungal infection that can lead to major dermatological and systemic health problems, is Candida albicans. Over the past 20 years, cutaneous candidiasis has become more prevalent, especially in hospitalized or immunocompromised patients. Conventional treatment methods employ antifungal drugs like azoles and polyenes, which are effective but have drawbacks because of their high recurrence rates, negative side effects, and growing antifungal resistance.
View Article and Find Full Text PDFObjectives: (formerly ) is a leading cause of invasive candidiasis and rapidly develops antifungal drug resistance during treatment. An increasing number of clinical isolates shows reduced susceptibility to echinocandins and azoles, leaving amphotericin B (AMB) as a last therapeutic option. Resistance of to this drug is rare and its underlying mechanisms are still not fully understood.
View Article and Find Full Text PDF